| Date | Form | Description | Docs | XBRL | Pages |
| 03/31/99 | 10-K/A | Annual report pursuant to section 13 and 15(d) |
|
13 | |
| 03/16/99 | 10-Q | Quarterly report pursuant to sections 13 or 15(d) |
|
16 | |
| 01/29/99 | 10-K405 | Annual report [Sections 13 and 15(d), S-K Item 405] |
|
42 | |
| 09/14/98 | 10-Q | Quarterly report pursuant to sections 13 or 15(d) |
|
15 | |
| 06/29/98 | DEF 14A | Definitive proxy statements |
|
9 | |
| 06/15/98 | 10-Q | Quarterly report pursuant to sections 13 or 15(d) |
|
14 | |
| 03/17/98 | 10-Q | Quarterly report pursuant to sections 13 or 15(d) |
|
13 | |
| 01/29/98 | 10-K405 | Annual report [Sections 13 and 15(d), S-K Item 405] |
|
40 | |
| 09/12/97 | 10-Q | Quarterly report pursuant to sections 13 or 15(d) |
|
17 | |
| 06/23/97 | DEF 14A | Definitive proxy statements |
|
9 |
Latest News & Events
Anixa Biosciences Announces Transfer of IND for Breast Cancer Vaccine from Cleveland Clinic
Read More...Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants
Read More...Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Monday, December 15, 2025
Read More...